Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 9/20 | 0.42 |
| ▸ | RXRB | P28702 | 5/20 | 0.42 |
| ▸ | RARB | P10826 | 9/20 | 0.42 |
| ▸ | RARG | P13631 | 8/20 | 0.42 |
| ▸ | RARA | P10276 | 6/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240160 | 0.88 | NPC1 (0.45) | NPC1RAB9AMAPTHSD17B1RXRA | |
| SCHEMBL18740981 | 0.80 | NPC1 (0.50) | NPC1RAB9AMAPTHSD17B1RXRA | |
| SCHEMBL31084998 | 0.80 | NPC1 (0.50) | NPC1RAB9AMAPTHSD17B1RXRA | |
| SCHEMBL1806400 | 0.79 | PBRM1 (0.49) | MAPTHSD17B1KDM4EALDH1A1LMNA | |
| SCHEMBL5648628 | 0.77 | PGR (0.49) | KDM4EALDH1A1CYP1A2POLBCYP3A4 | |
| SCHEMBL7642401 | 0.76 | RARB (0.67) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL2195224 | 0.76 | RXRA (0.66) | NPC1RAB9ARXRARXRBRARB | |
| SCHEMBL24055007 | 0.76 | PGR (0.50) | S100A4PGR | |
| SCHEMBL3893981 | 0.76 | MALT1 (0.41) | S100A4L3MBTL1PGR | |
| SCHEMBL12516220 | 0.76 | MAPT (0.53) | NPC1RAB9AMAPTHSD17B1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530565-A1 | SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2005-05-18 | — | — | EP | claimed |
| WO-2004009582-A1 | SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2004-01-29 | — | — | WO | claimed |
| EP-0871630-A1 | 4a,5a,8a,8b-TETRAHYDRO-6H-PYRROLO 3,4':4,5]FURO(3,2-b)PYRIDINE-6,8 7H]-DIONE DERIVATIVES FOR USE IN CONTROLLING ENDOPARASITES AND A METHOD OF PRODUCING SAID DERIVATIVES | BAYER AG (DE) | 1998-10-21 | — | — | EP | claimed |
| WO-1997014695-A1 | 4a,5a,8a,8b-TETRAHYDRO-6H-PYRROLO[3,4':4,5]FURO(3,2-b)PYRIDINE-6,8[7H]-DIONE DERIVATIVES FOR USE IN CONTROLLING ENDOPARASITES AND A METHOD OF PRODUCING SAID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-24 | — | — | WO | claimed |
| US-6942980-B1 | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities | ALLERGAN, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1535919-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Allergan, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6855832-B2 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-6818775-B2 | TREATMENT OF SKIN-RELATED DISEASES OR PREVENTION OF CERTAIN UNDESIRED SIDE EFFECTS OF ADMINISTERED RETINOIDS | ALLERGAN, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20040127469-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | JOHNSON ALAN T (US) | 2004-07-01 | — | — | US | disclosed |
| EP-0915825-B1 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1042313-B1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | ALLERGAN INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6720425-B2 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-5776699-A | MEASURING GENE EXPRESSION | ALLERGAN, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5773594-A | TREATING SKIN DISORDERS, REDUCING SIDE EFFECTS OF OTHER RETINOIDS | ALLERGAN (US) | 1998-06-30 | — | — | US | disclosed |
| US-5763635-A | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN (US) | 1998-06-09 | — | — | US | disclosed |
| US-5747542-A | SKIN DISORDERS; ANTICANCER AGENTS | ALLERGAN (US) | 1998-05-05 | — | — | US | disclosed |
| US-5741896-A | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN (US) | 1998-04-21 | — | — | US | disclosed |
| US-5723666-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION | ALLERGAN (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1997048672-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127469-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | NPC1 490/4885RAB9A 1484/4885MAPT 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.